Novo Nordisk's (NVO) 澳洲幸运5官方开奖结果体彩🍨网:American depositary receipts (ADRs) slipped in pre-market trading Wednesday morning after rising sales of the company's weight-loss drugs failed to boost earnings to the level of growth 澳洲幸运5官方开奖结果体彩网:analysts expected for the quarter.

The Danish company behind Ozempic and Wegovy saw a 25% year-over-year jump in revenue to 68.06 billion Danish kroner ($9.96 billion), but that was less than analysts expected. 澳洲幸运5官方开奖结果体彩网:Net income grew 3% to 20.05 billion kroner, also missing projections.

Novo Nordisk Raises Salܫe𒊎s Outlook, Lowers Profit Guidance

"The growth is driven by the 澳洲幸运5官方开奖结果体彩网:increased demand for our GLP-1-baseꦿd diabetes and obesity treatments, and we continue to reach more patients with our innovative treatments," Novo Nordisk CEO Lars Fruergaard Jørgensen said.

Ozempic sales rose 30% overall and 49% in the U.S. compared to the same time last year, while Wegovy sales jumped 53% globally and 36% in the U.S. market.

Novo Nordisk said it now anticipates full-year sales growth of between 22% to🔴 28%, up from 19% to 27% previously. However, the company lowered its projected operating🔯 profit growth to 20% to 28%, down from 22% to 30% previously.

Projections still include occasional supply shortages of Ozempic and Wegovy, as Novo Nordisk works to increase production capacity, and said its acquisition of three plants as part of its 澳洲幸运5官方开奖结果体彩网:purchase of syringe maker Catalent is expected to close by the end of 2024.

Novo Nordisk ADRs were down💦 over 3% to $125.65 in pre-market trading as of 8:35 a.m. ET Wednesday following the earnings release.